ALK’s EURneffy 1mg Secures the CHMP Positive Opinion to Treat Allergic Reactions in Children

Shots: The CHMP has recommended EURneffy 1mg (adrenaline nasal spray) to treat allergic reactions as well as idiopathic or exercise-induced anaphylaxis in children (≥4yrs. & 15-30kg) If granted, the approval would be valid in all 30 EEA states & will support an extension to the existing EURneffy 2 mg’s approval from Aug 2024 for emergency…

ByRidhi RastogiJanuary 30, 2026

ARS Pharmaceuticals Reports NMPA Approval of neffy 2mg (Epinephrine Nasal Spray) to Treat Type I Allergic Reactions

Shots: The Chinese NMPA has approved neffy 2mg for the emergency treatment of type I allergic reactions (anaphylaxis) in adults & children (≥30kg), with availability anticipated in the spring of 2026. Filing for neffy 1mg for children (15 to <30kg) to the NMPA is expected in the coming mos. In 2021, ARS Pharma licensed neffy…

ByRidhi RastogiDecember 30, 2025

ARS Pharmaceuticals and ALK’s EURneffy Secures the MHRA’s Approval to Treat Allergic Reactions in Children

Shots: The UK’s MHRA has approved EURneffy 2mg (adrenaline nasal spray) to treat allergic reactions (anaphylaxis) in children (>30kg); commercially available in the UK by late Q3’25 In Nov 2024, ARS Pharma granted ALK exclusive rights to commercialize neffy outside the US, incl. EU (as EURneffy), Canada, & select markets in exchange for $145M upfront, ~$320M…

ByRidhi RastogiJuly 21, 2025

ALK’s EURneffy 1mg Secures the CHMP Positive Opinion to Treat Allergic Reactions in Children

ARS Pharmaceuticals Reports NMPA Approval of neffy 2mg (Epinephrine Nasal Spray) to Treat Type I Allergic Reactions

ARS Pharmaceuticals and ALK’s EURneffy Secures the MHRA’s Approval to Treat Allergic Reactions in Children

Contact US

FOLLOW US